Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp grew its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,542,962 shares of the biopharmaceutical company’s stock after buying an additional 186,008 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned 0.13% of Bristol-Myers Squibb worth $143,830,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in BMY. PKS Advisory Services LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $304,000. Prestige Wealth Management Group LLC lifted its stake in Bristol-Myers Squibb by 1.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 28,778 shares of the biopharmaceutical company’s stock valued at $1,628,000 after buying an additional 403 shares in the last quarter. Signature Estate & Investment Advisors LLC boosted its holdings in Bristol-Myers Squibb by 46.6% in the 4th quarter. Signature Estate & Investment Advisors LLC now owns 8,724 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 2,775 shares during the last quarter. Zions Bancorporation N.A. increased its stake in Bristol-Myers Squibb by 12.2% during the 4th quarter. Zions Bancorporation N.A. now owns 188,331 shares of the biopharmaceutical company’s stock worth $10,652,000 after buying an additional 20,480 shares in the last quarter. Finally, GQG Partners LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $2,990,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. Truist Financial lifted their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Citigroup raised their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Bank of America reaffirmed a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Finally, Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their target price for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $57.86.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the business’s stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Stock Up 0.0 %

Shares of BMY opened at $61.09 on Tuesday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The firm has a market cap of $123.98 billion, a P/E ratio of -13.82, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The company’s 50-day moving average price is $58.29 and its 200 day moving average price is $56.05. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.06%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.